Intra-Cellular Therapies Inc. (ITCI)
| Market Cap | 5.59B |
| Revenue (ttm) | 102.92M |
| Net Income (ttm) | -303.50M |
| Shares Out | 94.32M |
| EPS (ttm) | -3.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 576,407 |
| Open | 59.92 |
| Previous Close | 58.92 |
| Day's Range | 58.59 - 60.11 |
| 52-Week Range | 28.40 - 66.00 |
| Beta | 1.19 |
| Analysts | Buy |
| Price Target | 72.32 (+22.1%) |
| Earnings Date | May 10, 2022 |
About ITCI
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as s...
Financial Performance
In 2021, ITCI's revenue was $83.80 million, an increase of 267.35% compared to the previous year's $22.81 million. Losses were -$284.13 million, 25.2% more than in 2020.
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for ITCI stock is "Buy." The 12-month stock price forecast is 72.32, which is an increase of 22.06% from the latest price.
News
Why Intra-Cellular Therapies Stock Rose 21.4% This Week
Strong sales for the company's only marketed therapy piqued investors' interest.
Why Intra-Cellular Therapies Trounced the S&P 500 Today
The biotech notches an extremely convincing first-quarter earnings beat.
Robust Uptake Of Antipsychotic Drug Boosts Intra-Cellular's Q1 Earnings
Intra-Cellular Therapies Inc's (NASDAQ: ITCI) Q1 revenues reached $35.0 million, compared to $15.9 million a year ago, beating the consensus of $33.65 million. Net product revenues of Caplyta were $34.8...
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 16.13% and 5.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update
First quarter 2022 results reflect strong CAPLYTA ® (lumateperone) launch in bipolar depression
Analysts Estimate Intra-Cellular Therapies (ITCI) to Report a Decline in Earnings: What to Look Out for
Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 0% and 3.58%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
Received FDA approval for CAPLYTA ® (lumateperone) for the treatment of bipolar depression in adults.
Why Earnings Season Could Be Great for Intra-Cellular Therapies (ITCI)
Intra-Cellular Therapies (ITCI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast
NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervou...
Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Intra-Cellular (ITCI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intra-Cellular Therapies to Present at the 11th Annual SVB Leerink Global Healthcare Conference
NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervou...
Strength Seen in Intra-Cellular (ITCI): Can Its 9.8% Jump Turn into More Strength?
Intra-Cellular (ITCI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down th...
Intra-Cellular Therapies Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' O...
NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervou...
Intra-Cellular Therapies Prices Public Offering of Common Stock
NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervou...
Why Intra-Cellular Therapies Took a Big Hit Today
The company is floating at least $400 million worth of its common stock.
IntraCellular Seeks To Raise $400M Via Equity To Fund Commercialization Of Schizophrenia Med
Intra-Cellular Therapies Inc (NASDAQ: ITCI) commenced an underwritten public offering of $400 million of shares. Underwriters have an option to purchase up to an additional 15% of the shares of common s...
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
NEW YORK, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervou...
FDA Approves Intra-Cellular's Antipsychotic For Bipolar Depression
The FDA has approved Intra-Cellular Therapies Inc (NASDAQ: ITCI) Caplyta for depressive episodes associated with bipolar I or II disorder in adults. The approval for Caplyta comes as monotherapy and as ...
Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depressi...
CAPLYTA is the only FDA-approved treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy and as adjunctive therapy with lithium or valpro...
Intra-Cellular Therapies Mourns the Passing of Director, Dr. Richard Lerner
NEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous...
Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates
Intra-Cellular (ITCI) delivered earnings and revenue surprises of -6.74% and 1.16%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular Therapies: Q3 Earnings Insights
Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q3 earnings results on Tuesday, November 9, 2021 at 08:00 AM. Here's what investors need to know about the announcement.
Intra-Cellular Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update
CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression are under review by the FDA, with a PDUFA target action date of December 17, 2021.